Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop (Second from left)
Managing Director & CEO, Paul Hyslop (Second from left)
Source: Zoono Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against COVID-19
  • Laboratory tests show the product is more than 99.99 per cent effective against the virus
  • Z-71 is the same technology used in the company’s hand sanitiser
  • Zoono’s products are known to protect humans against a variety of viruses for up to 30 days on surfaces and 24 hours on hands
  • Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share

Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against the recent coronavirus (COVIOD-19).

Laboratory tests show the product is more than 99.99 per cent effective against the virus.

COVID-19 has become a global concern and has been shown to survive on surfaces for up to nine days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Z-71 was previously tested against bovine coronavirus, however, this latest strain required new testing.

The company conducted two separate tests to EN Standard 14476:2013+A2:2019 for chemical disinfectants and antiseptics.

EN14476 is the European Standard that applies to products within the medical area, this includes hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding and others.

Z-71 Microbe Shield is the same technology used in the company’s hand sanitisers.

“Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus,” the company told the market.

Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share at 11:31 am AEDT.

zno by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…